Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | STS | P08842 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17545408 | 0.88 | NOTUM (0.45) | NOTUMGPR119STSESR2UCHL1 | |
| SCHEMBL18391882 | 0.87 | NOTUM (0.44) | NOTUMGPR119STSESR2UCHL1 | |
| SCHEMBL19219780 | 0.84 | NOTUM (0.66) | NOTUMMAPK1GAA | |
| SCHEMBL2109995 | 0.82 | NOTUM (0.46) | NOTUMGPR119ESR2UCHL1MAPK1 | |
| SCHEMBL3902271 | 0.81 | CNR2 (0.52) | NOTUMGPR119ESR2UCHL1MAPK1 | |
| SCHEMBL18391880 | 0.81 | NOTUM (0.39) | NOTUMGPR119STSESR2UCHL1 | |
| SCHEMBL23293654 | 0.80 | NR1H2 (0.46) | NOTUMGPR119ESR2UCHL1MAPK1 | |
| SCHEMBL16123405 | 0.80 | UCHL1 (0.51) | NOTUMGPR119ESR2UCHL1MAPK1 | |
| SCHEMBL31389170 | 0.80 | NR1H2 (0.46) | NOTUMGPR119ESR2UCHL1MAPK1 | |
| SCHEMBL31443362 | 0.80 | UCHL1 (0.48) | NOTUMGPR119STSUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626087-B2 | Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190084932-A1 | INDOLINE AND TETRAHYDROQUINOLINE SULFONYL INHIBITORS OF DIMETALLOENZYMES AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-21 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| WO-2017011408-A1 | INDOLINE AND TETRAHYDROQUINOLINE SULFONYL INHIBITORS OF DIMETALLOENZYMES AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084932-A1 | INDOLINE AND TETRAHYDROQUINOLINE SULFONYL INHIBITORS OF DIMETALLOENZYMES AND USE OF THE SAME | MGAM, NNMT, INMT | NOTUM 277/4885GPR119 2698/4885STS 101/4885 |
| US-10626087-B2 | Indoline and tetrahydroquinoline sulfonyl inhibitors of dimetalloenzymes and use of the same | MGAM, INMT, NNMT | NOTUM 201/4885GPR119 3208/4885STS 105/4885 |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | NOTUM 581/4885GPR119 4545/4885STS 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.